News / USA

US Launches Campaign Against Alzheimer's, Including Prevention Drug Trials

US Health and Human Services Secretary Kathleen Sebelius (file photo)US Health and Human Services Secretary Kathleen Sebelius (file photo)
x
US Health and Human Services Secretary Kathleen Sebelius (file photo)
US Health and Human Services Secretary Kathleen Sebelius (file photo)
Jessica Berman
The U.S. government has announced a major education and research campaign to fight Alzheimer's disease.  As part of that effort, scientists are stepping up their efforts to develop drugs by the middle of the next decade that could prevent the incurable brain-wasting disease.  

Two Alzheimer's disease prevention trials are receiving money from the National Institutes of Health, or NIH, as part of the Obama administration's new national strategy to fight the growing problem of Alzheimer's in the U.S. and around the world.  

An estimated 5.4 million Americans suffer from Alzheimer's or some form of dementia.  The number is expected to grow exponentially as the U.S. population ages, and reach 7.7 million by 2030.  By then, Alzheimer's and other dementia disorders could be affecting as many as 66 million people worldwide.

The so-called National Alzheimer's Plan calls on scientists to develop treatments to prevent the disease by 2025. NIH has set aside $50 million to help fund the effort.  NIH director Francis Collins says the studies herald a new era in Alzheimer's disease research.

"We have learned more about this disease in the last couple of years than probably ever before," said Collins. "And now the goal is to take that and translate it into interventions."

Collins was speaking at an NIH-sponsored conference of the nation's top Alzheimer's researchers.

Scientists at the Banner Alzheimer's Institute in Arizona announced they will be conducting human trials early next year of an experimental drug, called crenezumab, that they hope will prevent the disease.

The study will involve members of a large extended family living in remote villages within several hundred kilometers of each other near Medellin, Colombia.  Some of the thousands of relatives carry an extremely a rare genetic mutation that inevitably causes early on-set Alzheimer's.  

Those with the genetic flaw begin showing cognitive declines in their mid-forties and are destined to develop full-blown Alzheimer's by their early 50's.

The Banner Institute's Pierre Tariot is one of the lead investigators. Addressing the ethical questions some critics have raised about testing drugs on healthy people in a poor developing country, Tariot says all of the study participants have been fully informed about the possibility that the drug might not work, or that they might get a placebo that does not contain crenezumab.  

Tariot says they still wanted to participate.

"They have been faced with this devastating illness hitting every generation for hundreds of years," said Tariot. "As one of them put it, 'There are many rivers to cross but at least we are at the first bank.'  And that's kind of the attitude that people have had."

Three hundred individuals have signed up for the trial; one-third will receive crenezumab and the others will be given a placebo. The trial will also include a smaller number of individuals in the United States.

If the therapy works in those with early-onset disease, scientists hope it may also help older individuals.

Cremezumab is a vaccine that targets the brain plaques or amyloid protein deposits that are thought to underlie development of Alzheimer's, according to Banner's Eric Reiman, who will help lead the study.

"Crenezumab is an antibody treatment that is intended to bind with amyloid and remove it from the brain," said Reiman.

Injections of crenezumab or placebo will be administered every two weeks.  

The $100-million Colombia trial is slated to last five years, but researchers predict they could see results within two.  NIH is providing $16 million to support the research; Banner is contributing another $15 million.  The major share of the funding - about $65 million - will come from the drug's American manufacturer, Genentech.

A second Alzheimer's drug trial, also funded by NIH, has shown that a nasal insulin spray used twice daily by people with mild cognitive dysfunction seemed to improve their symptoms, offering hope that Alzheimer's could be treated or even prevented.

You May Like

UN Watchdog Urges Israel to Probe Possible Gaza War Crimes

More than 2,100 Palestinians, most of them civilians, were killed in a 51-day war in Gaza, along with 67 Israeli soldiers and six civilians in Israel More

New Kenyan 'Thin SIMs' Poised to Transform African Mobile Money

Equity's new technology is approved in African nation for one-year trial, though industry leader Safaricom says thin SIMs could lead to data theft and fraud More

Solar's Future Looks Brighter

New technology and dropping prices are contributing to a surge in solar power More

Featured Videos

Your JavaScript is turned off or you have an old version of Adobe's Flash Player. Get the latest Flash player.
Talks to Resume on Winter Gas for Ukrainei
X
Al Pessin
October 25, 2014 4:21 PM
Ukrainian and Russian officials will meet again next week in an effort to settle their dispute over natural gas supplies that threatens to leave Ukraine short of heating fuel for the coming winter. VOA’s Al Pessin reports from London the dispute is complex, and has both economic and geopolitical dimensions.
Video

Video Talks to Resume on Winter Gas for Ukraine

Ukrainian and Russian officials will meet again next week in an effort to settle their dispute over natural gas supplies that threatens to leave Ukraine short of heating fuel for the coming winter. VOA’s Al Pessin reports from London the dispute is complex, and has both economic and geopolitical dimensions.
Video

Video Smugglers Offer Cheap Passage From Turkey to Syria

Smugglers in Turkey offer a relatively cheap passage across the border into Syria. Ankara has stepped up efforts to stem the flow of foreign fighters who want to join Islamic State militants fighting for control of the Syrian border city of Kobani. But porous borders and border guards who can be bribed make illegal border crossings quite easy. Zlatica Hoke has more.
Video

Video China Political Meeting Seeks to Improve Rule of Law

China’s communist leaders will host a top level political meeting this week, called the Fourth Plenum, and for the first time in the party’s history, rule of law will be a key item on the agenda. Analysts and Chinese media reports say the meetings could see the approval of long-awaited measures aimed at giving courts more independence and include steps to enhance an already aggressive and high-reaching anti-corruption drive. VOA’s Bill Ide has more from Beijing.
Video

Video After Decades of Pressure, Luxembourg Drops Bank Secrecy Rules

European Union finance ministers have reached a breakthrough agreement that will make it more difficult for tax cheats to hide their money. The new legislation, which had been blocked for years by countries with a reputation as tax havens, was approved last week after Luxembourg and Austria agreed to lift their vetoes. But as Mil Arcega reports, it doesn’t mean tax cheats have run out of places to keep their money hidden.
Video

Video Kobani Refugees Welcome, Turkey Criticizes, US Airdrop

Residents of Kobani in northern Syria have welcomed the airdrop of weapons, ammunition and medicine to Kurdish militia who are resisting the seizure of their city by Islamic State militants. The Turkish government, however, has criticized the operation. VOA’s Scott Bobb reports from southeastern Turkey, across the border from Kobani.
Video

Video US ‘Death Cafes’ Put Focus on the Finale

In contemporary America, death usually is a topic to be avoided. But the growing “death café” movement encourages people to discuss their fears and desires about their final moments. VOA’s Jerome Socolovsky reports.
Video

Video Ebola Orphanage Opens in Sierra Leone

Sierra Leone's first Ebola orphanage has opened in the Kailahun district. Hundreds of children orphaned since the beginning of the Ebola outbreak face stigma and rejection with nobody to care for them. Adam Bailes reports for VOA about a new interim care center that's aimed at helping the growing number of children affected by Ebola.

All About America

AppleAndroid